Latest Tegal Corp (CLRX) Headlines
CollabRx Appoints Clifford Baron as Chief Operating Officer
GlobeNewswire - Wed Mar 05, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Clifford Baron, PhD as Vice President and Chief Operating Officer. Mr. Baron's most recent position was with Accelrys, Inc. a $160M+ global software provider serving pharmaceutical, biotechnology, chemical, and materials corporations.
Taglich Brothers Initiates Coverage on CollabRx, Inc.
Marketwire - Mon Mar 03, 9:01AM CST
Taglich Brothers, Inc. announces it initiated coverage of CollabRx, Inc.
10-Q: COLLABRX, INC.
Edgar Online - Thu Feb 13, 1:06PM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - (Amounts in thousands)
CollabRx Reports Third Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Tue Feb 11, 3:01PM CST
CollabRx, Inc. (the "Company") (Nasdaq:CLRX) today announced financial results for the third quarter of fiscal year 2014, which ended December 31, 2013.
CollabRx, Inc. Schedules Third Quarter Fiscal Year 2014 Financial Conference Call and Business Update
GlobeNewswire - Fri Jan 31, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on genomics, today announced that it will hold an investor conference call on February 11, 2014 to discuss the Company's financial results for the third quarter of fiscal 2014 and to provide an update about the business in the current fiscal year.
CollabRx and CellNetix Partner to Advance Molecular Testing in Oncology
M2 - Tue Jan 28, 9:37AM CST
CollabRx, Inc. (NASDAQ: CLRX) and CellNetix Pathology & Laboratories, LLC, have announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by CellNetix.
CollabRx to Present at the Sixth Annual Personalized Medicine World Conference
GlobeNewswire - Tue Jan 21, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, announces that Gavin J. Gordon, MBA, PhD, Vice President of Business Development & Strategic Alliances, will present in Track 2 (Big Data: Storage and Management) at the Personalized Medicine World Conference (PMWC) at 2 PM (PST) on January 28, 2014. The PMWC will be held January 26-28 at the Computer History Museum, 1401 N. Shoreline Blvd, Mountain View, California. The PMWC will include presentations and panel discussions from over 100 industry leaders from around the world.
CollabRx Launches New Web App for Cynvenio's ClearID Breast Cancer Patients
GlobeNewswire - Wed Jan 15, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a leading data analytics company, today announced that its newest Therapy Finder for breast cancer patients will be made available in connection with the Cynvenio ClearID(TM) Breast Cancer genomic blood test. This announcement extends the scope of a previously disclosed multi-year agreement which announced the pairing of the CollabRx Genetic Variant Annotation (GVA) Service(TM) with tumor mutation profiling from whole blood provided by Cynvenio.
Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
PRWeb - Wed Dec 11, 8:23AM CST
Cynvenio, a cancer diagnostics company focused on transforming cancer treatment and management through the genomic analysis of tumor cells in blood, today announced a multi-year agreement with CollabRx, Inc., a data analytics company focused on informing clinical decision making in molecular medicine, to offer clinical actionable reports built from CollabRx data and information services with Cynvenio genomic tests.
CollabRx and Cynvenio Partner in Molecular Diagnostics for Cancer
GlobeNewswire - Wed Dec 11, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, and Cynvenio Biosystems, Inc., a cancer diagnostics company, today announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by Cynvenio. The combined molecular testing and medical informatics solution will enable a more personalized approach to disease management by physicians who incorporate the results of molecular diagnostic testing into patient treatment planning.
CollabRx to Present at the LD MICRO Sixth Annual Conference
GlobeNewswire - Wed Nov 20, 1:36PM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, announces that Thomas R. Mika, Chief Executive Officer, will present at the LD MICRO Sixth Annual Conference at 11 a.m. (PST), Track 1, on December 3, 2013. The conference will be held December 3-5, 2013 at the Luxe Sunset Bel Air, 11461 Sunset Boulevard, Los Angeles, California. CollabRx management will be available during the day on December 3 for one-on-one meetings. Please contact LD MICRO to schedule a meeting.
CollabRx earnings show improvement over previous year Q2
M2 - Thu Nov 14, 6:09AM CST
CollabRx, Inc. (NASDAQ: CLRX) said its total operating revenue for the second quarter of fiscal 2014 was USD251,000, with the entire amount representing the company's commercialization of its content services and on-line media products.
CollabRx Reports Second Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Wed Nov 13, 3:02PM CST
CollabRx, Inc. (the "Company") (Nasdaq:CLRX) today announced financial results for the second quarter of fiscal year 2014, which ended September 30, 2013.
CollabRx Inc partners with Quest Diagnostics for clinical cancer genetic sequencing
M2 - Tue Nov 12, 10:37AM CST
Data analytics company CollabRx Inc (NasdaqCM:CLRX) reported on Monday the launch of a multi-year, non-exclusive agreement related to medical annotation for new next-generation sequencing test services for cancer.
CollabRx working with Quest Diagnostics in clinical genetic sequencing
M2 - Tue Nov 12, 7:42AM CST
CollabRx, Inc. (NASDAQ: CLRX) has announced a multi-year, non-exclusive agreement with Quest Diagnostics (NYSE: DGX), a provider of diagnostic information services related to medical annotation for new next-generation sequencing test services for cancer.
Nasdaq stocks posting largest volume increases
AP - Mon Nov 11, 5:11PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage increases
AP - Mon Nov 11, 12:25PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ZLCS, CLRX, DSCO and GALE added to NASDAQ Active Stock Watch List at GSR
ACCESSWIRE - Mon Nov 11, 9:19AM CST
New York, NY - (ACCESSWIRE) - 11/11/2013 - Growing Stock Report initiates its NASDAQ Active Stock Weekly Watch List adding Zalicus Inc. (NASDAQ:ZLCS), CollabRx, Inc. (NASDAQ:CLRX), Discovery Laboratories Inc. (NASDAQ
SCO) and Galena Biopharma, Inc. (NASDAQ:GALE).
CollabRx Teams With Quest Diagnostics in Clinical Genetic Sequencing
GlobeNewswire - Mon Nov 11, 6:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, today announced a multi-year, non-exclusive agreement with Quest Diagnostics (NYSEGX), the world's leading provider of diagnostic information services, related to medical annotation for new next-generation sequencing test services for cancer.
CollabRx Appoints Clifford Baron as Chief Operating Officer
GlobeNewswire - Wed Mar 05, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Clifford Baron, PhD as Vice President and Chief Operating Officer. Mr. Baron's most recent position was with Accelrys, Inc. a $160M+ global software provider serving pharmaceutical, biotechnology, chemical, and materials corporations.
Taglich Brothers Initiates Coverage on CollabRx, Inc.
Marketwire - Mon Mar 03, 9:01AM CST
Taglich Brothers, Inc. announces it initiated coverage of CollabRx, Inc.
10-Q: COLLABRX, INC.
Edgar Online - Thu Feb 13, 1:06PM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - (Amounts in thousands)
CollabRx Reports Third Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Tue Feb 11, 3:01PM CST
CollabRx, Inc. (the "Company") (Nasdaq:CLRX) today announced financial results for the third quarter of fiscal year 2014, which ended December 31, 2013.
CollabRx, Inc. Schedules Third Quarter Fiscal Year 2014 Financial Conference Call and Business Update
GlobeNewswire - Fri Jan 31, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on genomics, today announced that it will hold an investor conference call on February 11, 2014 to discuss the Company's financial results for the third quarter of fiscal 2014 and to provide an update about the business in the current fiscal year.
CollabRx and CellNetix Partner to Advance Molecular Testing in Oncology
M2 - Tue Jan 28, 9:37AM CST
CollabRx, Inc. (NASDAQ: CLRX) and CellNetix Pathology & Laboratories, LLC, have announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by CellNetix.
CollabRx to Present at the Sixth Annual Personalized Medicine World Conference
GlobeNewswire - Tue Jan 21, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, announces that Gavin J. Gordon, MBA, PhD, Vice President of Business Development & Strategic Alliances, will present in Track 2 (Big Data: Storage and Management) at the Personalized Medicine World Conference (PMWC) at 2 PM (PST) on January 28, 2014. The PMWC will be held January 26-28 at the Computer History Museum, 1401 N. Shoreline Blvd, Mountain View, California. The PMWC will include presentations and panel discussions from over 100 industry leaders from around the world.
CollabRx Launches New Web App for Cynvenio's ClearID Breast Cancer Patients
GlobeNewswire - Wed Jan 15, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a leading data analytics company, today announced that its newest Therapy Finder for breast cancer patients will be made available in connection with the Cynvenio ClearID(TM) Breast Cancer genomic blood test. This announcement extends the scope of a previously disclosed multi-year agreement which announced the pairing of the CollabRx Genetic Variant Annotation (GVA) Service(TM) with tumor mutation profiling from whole blood provided by Cynvenio.
Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
PRWeb - Wed Dec 11, 8:23AM CST
Cynvenio, a cancer diagnostics company focused on transforming cancer treatment and management through the genomic analysis of tumor cells in blood, today announced a multi-year agreement with CollabRx, Inc., a data analytics company focused on informing clinical decision making in molecular medicine, to offer clinical actionable reports built from CollabRx data and information services with Cynvenio genomic tests.
CollabRx and Cynvenio Partner in Molecular Diagnostics for Cancer
GlobeNewswire - Wed Dec 11, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, and Cynvenio Biosystems, Inc., a cancer diagnostics company, today announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by Cynvenio. The combined molecular testing and medical informatics solution will enable a more personalized approach to disease management by physicians who incorporate the results of molecular diagnostic testing into patient treatment planning.
CollabRx to Present at the LD MICRO Sixth Annual Conference
GlobeNewswire - Wed Nov 20, 1:36PM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, announces that Thomas R. Mika, Chief Executive Officer, will present at the LD MICRO Sixth Annual Conference at 11 a.m. (PST), Track 1, on December 3, 2013. The conference will be held December 3-5, 2013 at the Luxe Sunset Bel Air, 11461 Sunset Boulevard, Los Angeles, California. CollabRx management will be available during the day on December 3 for one-on-one meetings. Please contact LD MICRO to schedule a meeting.
CollabRx earnings show improvement over previous year Q2
M2 - Thu Nov 14, 6:09AM CST
CollabRx, Inc. (NASDAQ: CLRX) said its total operating revenue for the second quarter of fiscal 2014 was USD251,000, with the entire amount representing the company's commercialization of its content services and on-line media products.
CollabRx Reports Second Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Wed Nov 13, 3:02PM CST
CollabRx, Inc. (the "Company") (Nasdaq:CLRX) today announced financial results for the second quarter of fiscal year 2014, which ended September 30, 2013.
CollabRx Inc partners with Quest Diagnostics for clinical cancer genetic sequencing
M2 - Tue Nov 12, 10:37AM CST
Data analytics company CollabRx Inc (NasdaqCM:CLRX) reported on Monday the launch of a multi-year, non-exclusive agreement related to medical annotation for new next-generation sequencing test services for cancer.
CollabRx working with Quest Diagnostics in clinical genetic sequencing
M2 - Tue Nov 12, 7:42AM CST
CollabRx, Inc. (NASDAQ: CLRX) has announced a multi-year, non-exclusive agreement with Quest Diagnostics (NYSE: DGX), a provider of diagnostic information services related to medical annotation for new next-generation sequencing test services for cancer.
Nasdaq stocks posting largest volume increases
AP - Mon Nov 11, 5:11PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage increases
AP - Mon Nov 11, 12:25PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ZLCS, CLRX, DSCO and GALE added to NASDAQ Active Stock Watch List at GSR
ACCESSWIRE - Mon Nov 11, 9:19AM CST
New York, NY - (ACCESSWIRE) - 11/11/2013 - Growing Stock Report initiates its NASDAQ Active Stock Weekly Watch List adding Zalicus Inc. (NASDAQ:ZLCS), CollabRx, Inc. (NASDAQ:CLRX), Discovery Laboratories Inc. (NASDAQ
SCO) and Galena Biopharma, Inc. (NASDAQ:GALE). CollabRx Teams With Quest Diagnostics in Clinical Genetic Sequencing
GlobeNewswire - Mon Nov 11, 6:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, today announced a multi-year, non-exclusive agreement with Quest Diagnostics (NYSE
GX), the world's leading provider of diagnostic information services, related to medical annotation for new next-generation sequencing test services for cancer. 
